← All stories
Markets
Why Are Poolbeg Pharma And AIM's Life Science Names Trailing — investor outlook
Highlights Poolbeg Pharma sits in an AIM life science cohort that has trailed the resource-led rally. Clinical milestones and funding access, not commodity prices, drive small-cap biotech sentiment. London's junior board has been dominated…
Covered by 1 outlet
All coverage · 1 article